BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$27.85 USD
+3.23 (13.12%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $27.78 -0.07 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for BridgeBio Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -653.25 | -484.65 | -586.45 | -505.49 | -288.59 |
Depreciation/Amortization & Depletion | 6.49 | 6.77 | 5.84 | 3.09 | 0.00 |
Net Change from Assets/Liabilities | 5.06 | 28.08 | -4.40 | 14.93 | -10.92 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 113.98 | 30.31 | 87.07 | 87.75 | 45.91 |
Net Cash From Operating Activities | -527.72 | -419.49 | -497.93 | -399.71 | -253.59 |
Property & Equipment | -1.31 | -4.82 | -13.25 | -7.37 | -2.64 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 55.84 | 339.47 | -166.23 | -38.72 | -212.90 |
Other Investing Activities | -0.50 | 118.50 | -21.35 | -6.91 | -1.72 |
Net Cash from Investing Activities | 54.03 | 453.15 | -200.83 | -52.99 | -217.25 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 452.34 | 6.52 | -245.58 | -86.77 | 416.18 |
Issuance (Repayment) of Debt | 0.00 | -20.49 | 1,079.68 | 550.00 | 37.12 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
Other Financing Activities | -0.80 | 0.84 | -97.65 | -16.04 | -53.51 |
Net Cash from Financing Activities | 451.54 | -13.13 | 736.45 | 447.19 | 398.79 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -22.15 | 20.52 | 37.69 | -5.52 | -72.05 |
Cash at Beginning of Period | 416.88 | 396.37 | 358.68 | 364.20 | 436.25 |
Cash at End of Period | 394.73 | 416.88 | 396.37 | 358.68 | 364.20 |
Diluted Net EPS | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 |
Fiscal Year End for BridgeBio Pharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -111.70 | -36.16 | -653.25 | -482.92 | -303.44 |
Depreciation/Amortization & Depletion | 3.17 | 1.60 | 6.49 | 4.91 | 3.27 |
Net Change from Assets/Liabilities | 21.24 | -225.20 | 5.06 | -16.92 | -18.23 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -57.54 | 40.23 | 113.98 | 92.04 | 60.72 |
Net Cash From Operating Activities | -144.83 | -219.54 | -527.72 | -402.90 | -257.68 |
Property & Equipment | -0.75 | -0.70 | -1.31 | -0.87 | -0.44 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 4.15 | -1.44 | 55.84 | 55.47 | 17.36 |
Other Investing Activities | 22.39 | 24.89 | -0.50 | -0.50 | -0.50 |
Net Cash from Investing Activities | 25.79 | 22.75 | 54.03 | 54.10 | 16.42 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 313.22 | 315.22 | 452.34 | 454.56 | 144.46 |
Issuance (Repayment) of Debt | -23.42 | -23.42 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -15.99 | -12.25 | -0.80 | 1.50 | 4.56 |
Net Cash from Financing Activities | 273.82 | 279.55 | 451.54 | 456.06 | 149.02 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 154.78 | 82.76 | -22.15 | 107.26 | -92.24 |
Cash at Beginning of Period | 394.73 | 394.73 | 416.88 | 416.88 | 416.88 |
Cash at End of Period | 549.51 | 477.50 | 394.73 | 524.14 | 324.64 |
Diluted Net EPS | -0.39 | -0.20 | -0.97 | -1.08 | -0.98 |